Mercury Biopharmaceutical Corporation (TPEX:6932)

Market Cap	4.85B
Revenue (ttm)	4.96M
Net Income (ttm)	-50.57M
Shares Out	421.85M
EPS (ttm)	-0.12
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	811,063
Average Volume	730,071
Open	11.60
Previous Close	11.50
Day's Range	11.15 - 11.65
52-Week Range	10.40 - 17.60
Beta	-2.68
RSI	25.01
Earnings Date	May 27, 2025

About Mercury Biopharmaceutical

Mercury Biopharmaceutical Corporation engages in the development of drugs for unmet needs in Taiwan. The company develops StackDose platform, a drug development platform to produce new dosage forms with precise time-controlled dissolution, precise site absorption, and various dosage adjustments to enhance the bio-availability of active pharmaceutical ingredients to reduce the dosage of drugs and its side effects. It develops drugs for treating erectile dysfunction, pulmonary hypertension, sleep disorder, benign prostatic hyperplasia, angina pec...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2019
• Country: Taiwan
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 6932

Financial Performance

In 2024, Mercury Biopharmaceutical's revenue was 4.96 million, an increase of 380.45% compared to the previous year's 1.03 million. Losses were -50.57 million, 15.4% more than in 2023.